A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 4

Conditions: Infection; Pneumonia

Treatments: Drug: Comparator: tazocin / Duration of Treatment: 3 Days; Drug: Comparator: vancomycin / Duration of Treatment: 3 Days; Drug: MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days; Drug: Comparator: amikacin / Duration of Treatment: 3 Days

Study type: Interventional

Funder types: Industry

Identifiers

NCT00445094

2007_004

0787B-092

Details and patient eligibility

About

The primary objective of this study is a comparison between MK0787B and standard therapy.

Enrollment: 120 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Greater than 18 years of age
• Patient is diagnosed with nosocomial pneumonia

Exclusion criteria

• Immunological deficient patients
• Pregnant women and nursing mothers
• A fungus is identified before the study enrollment
• Received vancomycin or imipenem for more than 5 days before icu admission

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)